Official Journal of Research Center for Gastroenterology and Liver Diseases
Authors
The Fas receptor/ligand system including soluble forms is the most important apoptotic initiator in the liver. Dysregulation of this pathway may contribute to abnormal cell proliferation and cell death and is regarded as one of the mechanisms preventing the immune system from rejecting the tumor cells.
To analyze the role of Fas system Fas/ Fas ligand (Fas/ FasL) in the multi-step process of hepatic fibrosis/carcinogenesis, and to use of the serum markers as possible candidate biomarkers for early detection of hepatocellular carcinoma (HCC).
Ninety patients were enrolled: 30 cases of chronic hepatitis C (CHC) without cirrhosis, 30 cases of CHC with liver cirrhosis, and 30 cases of HCC and hepatitis V virus (HCV) infection. Ten wedge liver biopsies, taken during laparoscopic cholecystectomy, were served as normal controls. Serum soluble Fas (sFas) levels were measured using ELISA technique; Fas and FasL proteins were detected in hepatic tissue by indirect Immuno-histochemical technique (IHC); electron microscopic (EM) and immune electron microscopic examinations were performed for detection of Fas expression on lymphocytes.
Hepatic expression of both Fas and FasL as well as expression of Fas on separated lymphocytes were significantly increased in the diseased groups (P < 0. 01) compared to the control specimens. The highest expression was noticed in CHC specimens, particularly with the necro-inflammatory activity and advancement of the fibrosis. The sFas in cirrhotic patients and HCC were significantly higher than that in normal controls and CHC without cirrhosis group (P < 0.01).
Apoptosis and the Fas system were significantly involved in the process of converting liver cirrhosis into hepatocellular carcinoma. Down-regulation of Fas expression, up regulation of FasL expression in hepatocytes, and elevation of serum sFas levels were important in tumor evasion from immune surveillance, and in hepatic carcinogenesis.
© 2012, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Mohammadi A, Tajik N, Shah-Hosseini A, Alavian SM, Sharifi Z, et al. FAS and FAS-Ligand Promoter Polymorphisms in Hepatitis B Virus Infection. Hepat Mon. 2015;15(10):e26490. doi: https://doi.org/10.5812/hepatmon.26490
Fouad SA, Elsaaid NH, Mohamed NA, Abutaleb OM. Diagnostic Value of Serum Level of Soluble Tumor Necrosis Factor Receptor IIα in Egyptian Patients With Chronic Hepatitis C Virus Infection and Hepatocellular Carcinoma. Hepat Mon. 2014;14(9):e19346. doi: https://doi.org/10.5812/hepatmon.19346
Karami A, Alavian S, Najafi A, Hosseini M. Molecular Aspects of Hepatocellular Carcinoma Caused by Hepatitis C Virus. Hepat Mon. 2006;6(2):. doi:
Khajehahmadi Z, Tavilani H, Karimi J, Rafiee M, Arab-Sadeghabadi Z, et al. Non-Alcoholic Steatohepatitis and Autoimmune Hepatitis Cirrhosis May Have a Higher Risk of Progression to Hepatocellular Carcinoma. Hepat Mon. 2023;23(1):e138449. doi: https://doi.org/10.5812/hepatmon-138449
Sai W, Wang L, Zheng W, Yang J, Pan L, et al. Abnormal Expression of Golgi Protein 73 in Clinical Values and Their Role in HBV-Related Hepatocellular Carcinoma Diagnosis and Prognosis. Hepat Mon. 2015;15(12):e32918. doi: https://doi.org/10.5812/hepatmon.32918
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 1 month ago
Last Update: 4 days ago